Marker Therapeutics Announces $16.1 Million Private Placement
Funding Announcement: Marker Therapeutics, Inc. has secured $16.1 million through a private placement to support the clinical advancement of its MT-601 T cell therapy for lymphoma patients who have relapsed after or are ineligible for anti-CD19 CAR-T therapies.
Product Overview: MT-601 is a multi-antigen recognizing T cell product designed to target multiple tumor antigens in lymphoma cells, currently being evaluated in a Phase 1 APOLLO trial aimed at assessing its safety and efficacy.
Trade with 70% Backtested Accuracy
Analyst Views on MRKR
About MRKR
About the author
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Merakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium
- Scientific Exchange Platform: Merakris' Chief Scientific Officer, Dr. Roger Ilagan, has been invited to present at the Innovations in Wound Healing Symposium from December 11-14, 2025, sharing updates on MTX-001 to advance scientific dialogue in biologic drug development.
- Clinical Trial Progress: MTX-001, a first-in-class injectable biologic derived from cell-free amniotic fluid, is currently undergoing a multicenter Phase 2 trial (NCT04647240), with Part 1 completed and published in the International Wound Journal in March 2025, demonstrating promising safety and tolerability.
- Expanded Access Program: The therapy is available through an Expanded Access Program (EAP) for patients with cutaneous wounds, such as diabetic foot ulcers and pressure sores, reflecting Merakris' responsiveness to patient needs and market adaptability.
- Industry Leadership: Merakris is focused on developing biologically derived products to improve wound healing, showcasing its innovative leadership in regenerative medicine through advanced biologic manufacturing capabilities and a robust research pipeline.
Marker Therapeutics Announces Financial Results for Q3 2025 and Shares Business Developments
Clinical Study Results: The APOLLO study reported a 66% objective response rate and a 50% complete response rate for MT-601 in relapsed Non-Hodgkin lymphoma patients, demonstrating a favorable safety profile with no dose-limiting toxicities observed.
New Treatment Initiatives: Marker Therapeutics treated the first patient in the RAPID study, exploring Off-the-Shelf MAR-T cells for Acute Myeloid Leukemia and Myelodysplastic Syndrome, while also launching a clinical program for MT-601 in metastatic pancreatic cancer.
Manufacturing Collaboration: The company established a cGMP manufacturing partnership with Cellipont Bioservices to enhance production capabilities for MT-601, supporting clinical supply and future pivotal trials.
Financial Position: Marker Therapeutics raised approximately $10 million, extending its cash runway into 2026, with a reported net loss of $2 million for the third quarter of 2025, reflecting a decrease in research and development expenses compared to the previous year.
Marker Therapeutics to Present MT-601 Data for Relapsed Non-Hodgkin and Hodgkin Lymphoma at 67th ASH Annual Meeting
Study Overview: The Phase 1 APOLLO study is investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell therapy, in patients with relapsed B cell lymphomas, showing promising preliminary efficacy data with an objective response rate of 66% in Non-Hodgkin lymphoma and 78% in Hodgkin lymphoma.
Safety Profile: MT-601 demonstrated a robust safety profile with no dose limiting toxicities or immune-effector cell associated neurotoxicity syndrome reported, and only two participants experienced mild cytokine release syndrome.
Upcoming Presentations: Data from the APOLLO study will be presented in two posters at the 67th American Society of Hematology Annual Meeting from December 6-9, 2025, highlighting the safety and efficacy of MT-601 in relapsed or refractory lymphomas.
Company Background: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based therapies for hematological malignancies and solid tumors, with a commitment to operational excellence and patient outcome improvement.
Marker Therapeutics Shares Decline Following Lymphoma Treatment Report
Clinical Study Update: Marker Therapeutics provided an update on the Phase 1 APOLLO study of MT-601, a MAR-T cell product for lymphoma patients who have relapsed after anti-CD19 CAR-T therapy or are not eligible for it.
Efficacy Results: The study reported a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete responses. Hodgkin Lymphoma (HL) patients showed a 78% response rate, indicating MT-601's effectiveness across different lymphoma types.
Safety Profile: No dose-limiting toxicities were observed at the highest dose tested, and the treatment was well tolerated with minimal adverse events, including only two Grade 1 cytokine release syndrome cases.
Future Updates: Marker Therapeutics plans to provide additional data updates in the first half of 2026, while their stock price has seen a decline of 14.28% to $1.08 at the time of publication.
Marker Therapeutics Shares Positive Progress in Phase 1 APOLLO Study with Promising Response Rates in Relapsed Lymphoma
Study Results: The Phase 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma reported a 66% objective response rate, with 50% achieving complete response, demonstrating promising efficacy.
Safety Profile: The treatment exhibited a favorable safety profile, with no dose limiting toxicities or severe neurotoxicity observed, and only mild cytokine release syndrome events reported.
Next Steps: The study will proceed to a dose expansion phase to evaluate MT-601 at a maximum dose in patients with Diffuse Large B Cell Lymphoma (DLBCL) who are ineligible for CAR-T therapy.
Webcast Announcement: A live webcast is scheduled to discuss the clinical results and updates from the study, allowing attendees to engage through a Q&A feature.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Merakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium
- Scientific Exchange Platform: Merakris' Chief Scientific Officer, Dr. Roger Ilagan, has been invited to present at the Innovations in Wound Healing Symposium from December 11-14, 2025, sharing updates on MTX-001 to advance scientific dialogue in biologic drug development.
- Clinical Trial Progress: MTX-001, a first-in-class injectable biologic derived from cell-free amniotic fluid, is currently undergoing a multicenter Phase 2 trial (NCT04647240), with Part 1 completed and published in the International Wound Journal in March 2025, demonstrating promising safety and tolerability.
- Expanded Access Program: The therapy is available through an Expanded Access Program (EAP) for patients with cutaneous wounds, such as diabetic foot ulcers and pressure sores, reflecting Merakris' responsiveness to patient needs and market adaptability.
- Industry Leadership: Merakris is focused on developing biologically derived products to improve wound healing, showcasing its innovative leadership in regenerative medicine through advanced biologic manufacturing capabilities and a robust research pipeline.
Marker Therapeutics Announces Financial Results for Q3 2025 and Shares Business Developments
Clinical Study Results: The APOLLO study reported a 66% objective response rate and a 50% complete response rate for MT-601 in relapsed Non-Hodgkin lymphoma patients, demonstrating a favorable safety profile with no dose-limiting toxicities observed.
New Treatment Initiatives: Marker Therapeutics treated the first patient in the RAPID study, exploring Off-the-Shelf MAR-T cells for Acute Myeloid Leukemia and Myelodysplastic Syndrome, while also launching a clinical program for MT-601 in metastatic pancreatic cancer.
Manufacturing Collaboration: The company established a cGMP manufacturing partnership with Cellipont Bioservices to enhance production capabilities for MT-601, supporting clinical supply and future pivotal trials.
Financial Position: Marker Therapeutics raised approximately $10 million, extending its cash runway into 2026, with a reported net loss of $2 million for the third quarter of 2025, reflecting a decrease in research and development expenses compared to the previous year.
Marker Therapeutics to Present MT-601 Data for Relapsed Non-Hodgkin and Hodgkin Lymphoma at 67th ASH Annual Meeting
Study Overview: The Phase 1 APOLLO study is investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell therapy, in patients with relapsed B cell lymphomas, showing promising preliminary efficacy data with an objective response rate of 66% in Non-Hodgkin lymphoma and 78% in Hodgkin lymphoma.
Safety Profile: MT-601 demonstrated a robust safety profile with no dose limiting toxicities or immune-effector cell associated neurotoxicity syndrome reported, and only two participants experienced mild cytokine release syndrome.
Upcoming Presentations: Data from the APOLLO study will be presented in two posters at the 67th American Society of Hematology Annual Meeting from December 6-9, 2025, highlighting the safety and efficacy of MT-601 in relapsed or refractory lymphomas.
Company Background: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based therapies for hematological malignancies and solid tumors, with a commitment to operational excellence and patient outcome improvement.
Marker Therapeutics Shares Decline Following Lymphoma Treatment Report
Clinical Study Update: Marker Therapeutics provided an update on the Phase 1 APOLLO study of MT-601, a MAR-T cell product for lymphoma patients who have relapsed after anti-CD19 CAR-T therapy or are not eligible for it.
Efficacy Results: The study reported a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete responses. Hodgkin Lymphoma (HL) patients showed a 78% response rate, indicating MT-601's effectiveness across different lymphoma types.
Safety Profile: No dose-limiting toxicities were observed at the highest dose tested, and the treatment was well tolerated with minimal adverse events, including only two Grade 1 cytokine release syndrome cases.
Future Updates: Marker Therapeutics plans to provide additional data updates in the first half of 2026, while their stock price has seen a decline of 14.28% to $1.08 at the time of publication.
Marker Therapeutics Shares Positive Progress in Phase 1 APOLLO Study with Promising Response Rates in Relapsed Lymphoma
Study Results: The Phase 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma reported a 66% objective response rate, with 50% achieving complete response, demonstrating promising efficacy.
Safety Profile: The treatment exhibited a favorable safety profile, with no dose limiting toxicities or severe neurotoxicity observed, and only mild cytokine release syndrome events reported.
Next Steps: The study will proceed to a dose expansion phase to evaluate MT-601 at a maximum dose in patients with Diffuse Large B Cell Lymphoma (DLBCL) who are ineligible for CAR-T therapy.
Webcast Announcement: A live webcast is scheduled to discuss the clinical results and updates from the study, allowing attendees to engage through a Q&A feature.
